Newsletter
Strides Pharma is also stepping up its Africa play, and it’s doing it with a strong global partnership.
The deets: through its step-down subsidiary, Strides Pharma International AG (SPIAG), the company will acquire and in-license a portfolio of branded generic products from Sandoz AG across Sub-Saharan Africa.
Simply put, Strides is gaining both the products and the rights to sell them in key markets.
The deal spans four regions: Western Sahara (covering 10 countries), along with Ghana, Nigeria, and Kenya, markets with growing demand for affordable medicines.
The portfolio includes established brands across anti-infective, cardiovascular, and dermatology segments, with several products generating over $1 million in annual sales.
